Researchers have achieved a critical milestone in xenotransplantation by successfully demonstrating that gene-edited pig liver xenografts can function effectively in extracorporeal circulation with human blood. Published in Nature Medicine in July 2026, the study analyzed immune, coagulation, and metabolic responses across four human decedent trials, generating the first comprehensive molecular safety and efficacy profile for this emerging therapeutic approach.
The research identifies specific immune and coagulation pathways that activate during xenograft exposure, providing essential data to optimize clinical protocols. These findings represent a pivotal step toward addressing the critical global shortage of donor livers for transplantation and clearing the pathway for living patient trials within the next 2-5 years. The successful metabolic function and sustained viability of pig liver xenografts in human blood circulation demonstrates the scientific and clinical feasibility of xenograft-based liver support for patients with acute liver failure.
Read the full article on GMJ Newsroom.
Was this article helpful?
